IPA/CJC Blend

CJC-1295 No DAC + Ipamorelin (often called the “Gold Standard” GH-releasing combo or CJC/Ipa blend) is a synthetic peptide combination pairing CJC-1295 without DAC (Modified GRF 1-29) with Ipamorelin, typically provided in a single lyophilized vial (common ratios include 5 mg CJC-1295 No DAC + 5 mg Ipamorelin, 2 mg/2 mg, or 10 mg total blends). This research formulation has become one of the most widely studied and utilized growth hormone secretagogue stacks in preclinical models due to its potent synergistic stimulation of endogenous pulsatile growth hormone (GH) release while maintaining a remarkably clean side-effect profile. CJC-1295 No DAC acts as a GHRH analog to amplify GH pulse amplitude, while Ipamorelin functions as a selective ghrelin mimetic (GHS-R1a agonist) to increase pulse frequency and potency, resulting in supra-additive GH/IGF-1 elevation. Researchers employ this blend in laboratory and animal models to investigate mechanisms of GH axis physiology, body composition optimization, tissue repair, metabolic regulation, and age-related endocrine decline. As a research-grade compound, CJC-1295 No DAC + Ipamorelin is intended exclusively for in vitro and animal studies. Scientists value its near-physiological pulsatile GH pattern, minimal impact on cortisol/prolactin, lack of significant appetite stimulation, and exceptional synergy for studying maximal endogenous GH output without exogenous hormone administration.

Key Research Applications

• Pulsatile Growth Hormone and IGF-1 Amplification — Preclinical studies consistently demonstrate that the combination produces dramatically higher GH peaks and greater total GH/IGF-1 area-under-the-curve compared to either peptide alone. The synergy mimics youthful, multi-pulse GH secretion patterns while preserving negative feedback regulation.
• Body Composition and Anabolic Research — The blend promotes increases in lean muscle mass, improved nitrogen retention, enhanced protein synthesis, and reductions in fat mass in various animal models. It is frequently investigated in sarcopenia, cachexia, muscle wasting, post-injury recovery, and age-related body composition decline.
• Fat Metabolism and Lipolysis — Research shows enhanced lipolytic activity, increased fatty acid oxidation, and preferential reduction in visceral and subcutaneous fat depots, often attributed to elevated GH pulses and improved metabolic flexibility without significant insulin resistance.
• Tissue Repair and Recovery — The combination accelerates healing of muscle, tendon, ligament, cartilage, and bone injuries in preclinical models. Studies explore benefits in wound healing, connective tissue regeneration, post-surgical recovery, and counteracting catabolic states through elevated GH/IGF-1 axis activity.
• Anti-Aging and Metabolic Health — Investigations highlight potential improvements in insulin sensitivity (in certain dosing contexts), bone density, skin elasticity, sleep quality, and overall vitality markers. The clean profile makes it a favored tool for studying long-term GH restoration effects in aging and metabolic syndrome models.

Technical Specifications

• Composition: Blend of CJC-1295 No DAC (C₁₅₂H₂₅₂N₄₄O₄₂; MW 3367.9 g/mol) and Ipamorelin (C₃₈H₄₉N₉O₅; MW 711.85 g/mol), commonly provided as equal-part mixtures (e.g., 5 mg/5 mg total vial).
• Molecular Weight: Composite (~4,080 g/mol for equal parts).
• Sequences:
  • CJC-1295 No DAC: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂ (C-terminal amidation; substitutions: D-Ala², Gln⁸, Ala¹⁵, Leu²⁷)
  • Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (Aib = 2-aminoisobutyric acid; D-2-Nal = D-2-naphthylalanine; C-terminal amidation)